Guido Eibl
Impact in
- Oncology top 2%
- Pancreatic and Hepatic Oncology Research
- Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
Papers in
- Oncology 43
- Pancreatic and Hepatic Oncology Research 27
-
- Cancer, Lipids, and Metabolism 7
- Co-authors
- Oscar Joe Hines (42 shared papers)Enrique Rozengurt (23 shared papers)Howard A. Reber (30 shared papers)James W. Sinnett‐Smith (14 shared papers)Krisztina Kisfalvi (3 shared papers)Heinz Johannes Buhr (16 shared papers)John P. Duffy (4 shared papers)Aune Moro (15 shared papers)
- Journals
- Pancreas (18 papers)Surgery (6 papers)Cancers (4 papers)Cancer Research (4 papers)PLoS ONE (4 papers)
- Partner nations
- United StatesGermanyJapan
In The Last Decade
Guido Eibl
104 papers receiving 4.4k citations
Peers
Comparison fields: 5 of 124
- Oncology 1.7k
- Cancer Research 749
- Surgery 1.0k
- Molecular Biology 1.6k
- Pharmacology 332
Countries citing papers authored by Guido Eibl
This map shows the geographic impact of Guido Eibl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guido Eibl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guido Eibl more than expected).
Fields of papers citing papers by Guido Eibl
This network shows the impact of papers produced by Guido Eibl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guido Eibl. The network helps show where Guido Eibl may publish in the future.
Co-authors
The 25 scholars most cited alongside Guido Eibl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 108 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 368 | |
| 2 | 2009 | 271 | |
| 3 | 2011 | 156 | |
| 4 | 2003 | 143 | |
| 5 | 2018 | 121 | |
| 6 | 2017 | 112 | |
| 7 | 2008 | 110 | |
| 8 | 2017 | 108 | |
| 9 | 2003 | 107 | |
| 10 | 2007 | 102 | |
| 11 | 2018 | 101 | |
| 12 | 2001 | 93 | |
| 13 | 2005 | 93 | |
| 14 | 2004 | 91 | |
| 15 | 2016 | 90 | |
| 16 | 2013 | 77 | |
| 17 | 2009 | 74 | |
| 18 | 2014 | 69 | |
| 19 | 2000 | 68 | |
| 20 | 2017 | 67 |
About Guido Eibl
Guido Eibl is a scholar working on Oncology, Cancer Research, Surgery, Pharmacology and Molecular Biology, having authored 108 papers that have together received 4.5k indexed citations. Recurring topics across this work include Pancreatitis Pathology and Treatment (28 papers), Pancreatic and Hepatic Oncology Research (27 papers), Metabolism, Diabetes, and Cancer (14 papers), Inflammatory mediators and NSAID effects (12 papers), Cancer, Lipids, and Metabolism (7 papers), Electrolyte and hormonal disorders (7 papers), Hippo pathway signaling and YAP/TAZ (7 papers) and Peroxisome Proliferator-Activated Receptors (5 papers). The work is most often cited by research in Oncology (1.7k citations), Cancer Research (749 citations), Surgery (1.0k citations), Molecular Biology (1.6k citations) and Pharmacology (332 citations). Guido Eibl has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include Oscar Joe Hines, Enrique Rozengurt, Howard A. Reber, James W. Sinnett‐Smith, Krisztina Kisfalvi, Heinz Johannes Buhr, John P. Duffy, Aune Moro, Hui-Hua Chang and Hubert G. Hotz. Their work appears in journals such as Pancreas, Surgery, Cancers, Cancer Research and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.